Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 4
2001 1
2002 1
2003 2
2004 3
2005 3
2006 4
2007 3
2008 7
2009 12
2010 11
2011 6
2012 9
2013 8
2014 6
2015 3
2016 5
2017 8
2018 8
2019 4
2020 1
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24715380

96 results

Results by year

Filters applied: . Clear all
Page 1
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.
Migliaccio I, Wu MF, Gutierrez C, Malorni L, Mohsin SK, Allred DC, Hilsenbeck SG, Osborne CK, Weiss H, Lee AV. Migliaccio I, et al. Breast Cancer Res Treat. 2010 Oct;123(3):651-60. doi: 10.1007/s10549-009-0632-6. Epub 2009 Nov 19. Breast Cancer Res Treat. 2010. PMID: 19924529 Free PMC article.
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
Kensler KH, Regan MM, Heng YJ, Baker GM, Pyle ME, Schnitt SJ, Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi RM. Kensler KH, et al. Breast Cancer Res. 2019 Feb 22;21(1):30. doi: 10.1186/s13058-019-1118-z. Breast Cancer Res. 2019. PMID: 30795773 Free PMC article. Clinical Trial.
GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Liu J, Prager-van der Smissen WJ, Look MP, Sieuwerts AM, Smid M, Meijer-van Gelder ME, Foekens JA, Hollestelle A, Martens JW. Liu J, et al. Cancer Lett. 2016 Jun 28;376(1):104-9. doi: 10.1016/j.canlet.2016.03.038. Epub 2016 Mar 24. Cancer Lett. 2016. PMID: 27018307 Free article.
96 results